Bristol Myers Squibb to Acquire 2seventy bio

2seventy bio Announces Acquisition by 百时美施贵宝

In a strategic move set to enhance its gene therapy and oncology portfolio, 2seventy bio, Inc. has entered into a definitive merger agreement to be acquired by Bristol Myers Squibb (NYSE: BMY). The acquisition will see BMS purchasing all outstanding shares of 2seventy bio at $5.00 per share in an all-cash transaction valued at approximately $286 million, a remarkable 88% premium over 2seventy bio’s closing share price of $2.66 on March 7, 2025. The deal represents a significant step for both companies, as 2seventy bio has been focusing its efforts on Abecma, a leading CAR T-cell therapy for multiple myeloma.

Transaction Details and Path to Completion

As per the agreement, Bristol Myers Squibb will launch a tender offer to acquire all outstanding shares of 2seventy bio at $5.00 per share. The deal is expected to close in Q2 2025, subject to standard closing conditions, including the tender of the majority of shares and regulatory clearances under the Hart-Scott-Rodino Antitrust Improvements Act. Following the tender offer, BMS will proceed with a second-step merger to acquire any remaining shares. Following the successful completion, 2seventy bio’s common stock will be delisted from Nasdaq.

Key Stockholder Support

Certain stockholders of 2seventy bio, owning approximately 5.3% of the company’s shares, have already entered into tender and support agreements, confirming their intention to tender their shares in the offer.

Abecma: A Breakthrough Therapy for Multiple Myeloma

Abecma (idecabtagene vicleucel) is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T-cell immunotherapy approved for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more lines of therapy. As part of the transaction, Abecma will continue to be a key focus under Bristol Myers Squibb’s leadership.

Important Safety Information for Abecma

As a highly effective but complex treatment, Abecma comes with significant risks, including Cytokine Release Syndrome (CRS), neurologic toxicities, Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS), and prolonged cytopenia. Patients must be monitored closely for these adverse reactions following treatment. Abecma is only available through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS). For full prescribing information, please refer to the Medication Guide or visit Abecma REMS.

Looking Ahead: BMS's Oncology and Gene Therapy Leadership

Bristol Myers Squibb’s acquisition of 2seventy bio strengthens its leadership in cell and gene therapies, particularly in the oncology space. As the companies continue to expand their joint efforts, particularly in the development of innovative therapies like Abecma, this acquisition is expected to unlock more opportunities for patients with serious hematologic diseases.